Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

amgen_hq

NICE turns down Amgen’s multiple myeloma drug

November 9, 2016
Research and Development, Sales and Marketing Amgen, Kyprolis, NICE

Amgen has seen its drug Kyprolis (carfilzomib) rejected by NICE for its routine use in the treatment of multiple myeloma …

News
astrazeneca_building_white

AstraZeneca’s post-heart attack drug gets NICE recommendation

November 4, 2016
Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack

AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …

News
celgene_1_02

Celgene’s Otezla approved by NICE for chronic plaque psoriasis

October 20, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, NICE, apremilast, otezla

NICE has given its approval to another indication for Celgene’s Otezla (apremilast), meaning NHS patients now have access to the …

News

NICE plans new “fast-track” appraisal option

October 14, 2016
Medical Communications, Sales and Marketing NHS, NICE

The National Institute for Health and Care Excellence (NICE) has proposed the introduction of a fast-track process which could make …

News
janssen_latest_logo_on_sign

NICE knocks back Janssen rare disease drug

October 13, 2016
Medical Communications Janssen, NICE, imbruvica

NICE has announced its rejection of Janssen’s Imbruvica (ibrutinib) for the treatment of specific cases of Waldenstrom’s macroglobulinaemia (WM) – …

News

NICE backs Celgene’s Otezla for psoriatic arthritis

October 12, 2016
Research and Development, Sales and Marketing Celgene, NICE, otezla

The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …

News

NICE recommends Forxiga in Triple Therapy for Diabetes

October 7, 2016
Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes

The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …

News
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …

News
shutterstock_235920349

NICE and the CDF: Are they still up to scratch?

October 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE

Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …

Feature

NICE rejects Lilly lung cancer drug, recommends Bayer’s Xofigo and Amgen’s Imlygic

September 30, 2016
Medical Communications, Sales and Marketing Imlygic, NICE, Portrazza, xofigo

The National Institute of Health and Care Excellence has issued final guidance rejecting Eli Lilly’s Portrazza (necitumumab) for the treatment …

News
eylea-product-box-md

NICE approves Bayer’s Eylea for NHS use

September 28, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE

Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …

News
gilead-sciences

Provisional NICE recommendation for Gilead’s Hepatitis C treatment

September 28, 2016
Research and Development, Sales and Marketing Epclusa, NICE, hepatitis C

NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment …

News
roche__tree

NICE rejects expanded treatment indication for Roche’s Esbriet

September 19, 2016
Sales and Marketing Esbriet, NICE, Roche, rejection

NICE has published a final appraisal rejecting the expanded use of Roche’s Esbriet (pirfenidone) for the treatment of early idiopathic …

News

NICE recommends Bayer’s Xofigo for prostate cancer treatment

September 2, 2016
Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo

NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …

News

NICE approves lung cancer and leukaemia treatments

August 24, 2016
Research and Development, Sales and Marketing Alimta, CDF, NICE, bosulif, bosutinib, pemetrexed

The National Institute for Health and Care Excellence (NICE) has issued its approval of two drugs for routine use on …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026